and 5 Enterococcus strains isolated from healthy human infant gut can ameliorate aging-related metabolic, physical and cognitive dysfunctions in older mice. We show that the Feeding this probiotic cocktail prevented high-fat diet–induced (HFD-induced) abnormalities in glycose metabolism and physical functions in older mice and reduced microbiota dysbiosis, leaky gut, inflammation. Probiotic-modulated gut microbiota reduced leaky gut by increasing tight junctions on intestinal epithelia, which in turn reduced inflammation. Mechanistically, probiotics increased bile salt hydrolase activity in older microbiota, which in turn increased taurine deconjugation from bile acids to increase free taurine abundance in the gut. We further show that taurine stimulated tight junctions and suppressed gut leakiness. Further, taurine increased life span, reduced adiposity and leaky gut, and enhanced physical function in Caenorhabditis elegans. Whether this novel human origin probiotic therapy could prevent or treat aging-related leaky gut and inflammation in the elderly by reversing microbiome dysbiosis requires evaluation.

A PHASE 2B CLINICAL TRIAL ASSESSING LOMECEL-B INFUSION IN INDIVIDUALS WITH AGING FRAILTY: STUDY DESIGN AND RATIONALE

Kevin Ramdas,[1] Ben Hitchinson,[2] Lisa McClain-Moss,[2] Keyvan Yousefi,[3] Liliana Diaz,[2] Jorge Ruiz,[4] Joshua Hare,[2] and Anthony Oliva,[2] 1. *Longeveron, Inc. , Miami, Florida, United States, 2. Longeveron, Inc, Miami, Florida, United States, 3. Longeveron Inc., Miami, Florida, United States, 4. VAMC, Miami, Florida, United States*

Frailty is a common and important geriatric syndrome characterized by age-associated declines in physiology and function across multiple organ systems, which lead to increased vulnerability to adverse health outcomes. A biological mechanism that underlies the decline in physical function associated with aging frailty is chronic inflammation. The MSCs in Lomecel-B have immuno-modulatory capacity and control inflammation and the cytokine production of lymphocytes. An individual's endogenous stem cell production decreases with age, this decrease likely contributes to reduced ability to regenerate and repair organs and tissues. Aging Frailty represents an exciting potential indication for cellular based therapies like Lomecel-B. This study is intended to evaluate the effects of Lomecel-B infusion compared to placebo on mobility and exercise tolerance, patient-reported physical function assessments and biomarkers for inflammation in individuals with Aging Frailty. This is a randomized, double-blind placebo-controlled, parallel multi-arm multicenter study enrolling adults aged 70-85 years identified as mildly or moderately frail per the CSHA Clinical Frailty Scale (CFS), with reduced six minute walk test (6MWT) and elevated Tumor Necrosis Factor-α (TNF-α), at screening. 150 subjects (30 per group) were randomized to receive a single peripheral intravenous infusion of 25, 50, 100, or 200 million doses, or placebo. Safety and efficacy assessments were conducted at 30, 90, 180, and 270 days after infusion. A follow up telephone call to subjects was placed at 365 days. We describe the design and rationale in detail of this 2b study assessing the effects of Lomecel-B on older adults with Aging Frailty.

CLAIMS-BASED NETWORK ANALYSIS OF DISEASE PROGRESSIONS IN COMPLEX AND NON-COMPLEX OLDER ADULTS

Peter Nicholas Onglao,[1] Ciara Janer,[1] Maria Eloisa Ventura,[1] and Lauren Bangerter,[2] 1. *OptumLabs, Minnetonka, Minnesota, United States, 2. OptumLabs, Eden Prairie, Minnesota, United States*

Older adults are the fastest growing subset of complex patients with high medical, behavioral, and social needs. Understanding differences in disease progression patterns between complex and non-complex older adults is critical for understanding disease risk and tailoring patient-centered interventions. We identified complex patients as those having frequent medical encounters and multiple chronic conditions within the first year of the study period and non-complex patients as the converse. This study compares the disease progression patterns of (a) complex and (b) non-complex older adults by creating disease progression networks (DPN) from claims data of 762,362 patients (mean age = 73) from 2016 to 2020. We characterized the network size and density between the complex patient DPN (C-DPN) and non-complex patient DPN (NC-DPN), and compared disease progression incidence, time-to-progression, and age- and gender-related risk. Results show that the C-DPN was denser and had a wider range of values for risk of progression compared to the NC-DPN. This implies more varied disease progression patterns occurring in the complex adults. We were also able to compare (median) time-to-progressions of diseases relative to each subpopulation and found variation in disease progression time. Furthermore, k-means clustering on the network allowed us to identify highly connected diseases involved in many disease pathways that are prevalent among older adults. (e.g., lipoprotein disorders, hypertension, major depressive disorder). Our results suggest that DPNs can be used to identify important conditions and time-points for tailoring care to the complex and non-complex older adults.

EFFECTS OF SMOKING CESSATION ON EPIGENETIC AGING

Brian Chen,[1] Weiye Wang,[1] Nichole Rigby,[1] Randal Olson,[2] and Steve Sabes,[3] 1. *FOXO Technologies, Minneapolis, Minnesota, United States, 2. FOXO Technologies, FOXO Technologies, California, United States, 3. FOXO Technologies, FOXO Technologies, Minnesota, United States*

"Epigenetic clocks" have become widely used to assess individual rates of biological aging. However, experimental data are limited in humans to identify potential confounding factors that may influence one's rate of epigenetic aging and multiple health outcomes. We examined multiple epigenetic aging measures among regular smokers who quit smoking for two weeks. DNA methylation markers were assessed in both whole blood and saliva at multiple time points using a customized DNA methylation microarray. Generally, no changes in epigenetic aging rates were detected in the two week observation period with the exception of pronounced decreases over time in rate of Hannum's clock and Extrinsic Epigenetic Age Acceleration in blood DNA. In saliva DNA, decreases over time were detected in the rates of the GrimAge and DNAmPhenoAge clocks, but we saw an increase in the